B. Metzler seel. Sohn & Co. AG Buys New Position in Omnicell, Inc. $OMCL

B. Metzler seel. Sohn & Co. AG bought a new position in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 46,462 shares of the company's stock, valued at approximately $1,929,000. B. Metzler seel. Sohn & Co. AG owned 0.10% of Omnicell as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Raymond James Financial Inc. purchased a new position in shares of Omnicell during the 2nd quarter valued at about $26,000. Versant Capital Management Inc grew its holdings in Omnicell by 38.7% during the second quarter. Versant Capital Management Inc now owns 1,053 shares of the company's stock worth $44,000 after acquiring an additional 294 shares during the period. Clearstead Advisors LLC raised its position in Omnicell by 12,180.0% during the fourth quarter. Clearstead Advisors LLC now owns 1,228 shares of the company's stock valued at $56,000 after acquiring an additional 1,218 shares in the last quarter. Kemnay Advisory Services Inc. acquired a new position in Omnicell in the fourth quarter valued at approximately $58,000. Finally, Parkside Financial Bank & Trust grew its position in Omnicell by 1,708.1% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,338 shares of the company's stock valued at $61,000 after buying an additional 1,264 shares during the period. Institutional investors and hedge funds own 97.70% of the company's stock.

Analysts Set New Price Targets

OMCL has been the topic of several research analyst reports. KeyCorp lowered their price objective on Omnicell from $70.00 to $65.00 and set an "overweight" rating on the stock in a report on Friday, July 31st. Zacks Research cut Omnicell from a "hold" rating to a "strong sell" rating in a report on Friday, August 7th. Piper Sandler restated an "overweight" rating and issued a $45.00 target price (down from $55.00) on shares of Omnicell in a research report on Monday, August 3rd. Craig Hallum reiterated a "buy" rating and set a $55.00 price target on shares of Omnicell in a research report on Wednesday, April 29th. Finally, Wall Street Zen upgraded Omnicell from a "buy" rating to a "strong-buy" rating in a report on Sunday, May 10th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $57.86.

Omnicell Price Performance

Shares of OMCL opened at $35.58 on Friday. Omnicell, Inc. has a fifty-two week low of $29.06 and a fifty-two week high of $55.00. The firm's 50 day moving average price is $40.38 and its 200 day moving average price is $39.68. The company has a market cap of $1.62 billion, a P/E ratio of 42.36, a PEG ratio of 0.89 and a beta of 0.98. The company has a quick ratio of 1.43, a current ratio of 1.64 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.94 EPS for the quarter, topping the consensus estimate of $0.47 by $0.47. The company had revenue of $312.21 million during the quarter, compared to analysts' expectations of $310.21 million. Omnicell had a net margin of 3.13% and a return on equity of 5.66%. The firm's revenue was up 7.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.45 EPS. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. On average, research analysts forecast that Omnicell, Inc. will post 1.41 earnings per share for the current fiscal year.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company's offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell's analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.

Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source